Medtronic invests in CoreMap’s oversubscribed $37m Series C round
The funds raised will enable CoreMap to develop more precise data-driven tools to assist atrial fibrillation ablation. Read more: Medtronic invests in CoreMap’s oversubscribed $37m Series C round
Medtronic has invested in CoreMap's $37m Series C funding round, enabling the US-based medtech to create more precise data-driven tools for atrial fibrillation (AF) ablation. CoreMap, founded in 2016 and based in Burlington, Massachusetts, specializes in improving the diagnosis and treatment of AF, a common heart rhythm disorder characterized by irregular beats.
The company's electrophysiology mapping system, which provides physicians with guidance for AF ablation, will benefit from the funds raised. CEO and co-founder Sarah Kalil emphasized the significance of this financing milestone, stating that AF remains a major challenge in electrophysiology and that better data is crucial for treatment decisions and improved patient outcomes.
Medtronic's global head of corporate and business development, Chris Eso, expressed excitement about supporting CoreMap's next-generation AF mapping platform and accelerating its time to market.
Written by urgent.news from Silicon Republic's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
